Analysts Conflicted on These Healthcare Names: Stereotaxis (STXS) and Novavax (NVAX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Stereotaxis (STXS – Research Report) and Novavax (NVAX – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Stereotaxis (STXS)
Roth MKM analyst Kyle Bauser reiterated a Buy rating on Stereotaxis today and set a price target of $4.00. The company’s shares closed last Tuesday at $2.51.
According to TipRanks.com, Bauser is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Stereotaxis is a Strong Buy with an average price target of $4.20, representing a 57.9% upside. In a report released today, Lake Street also maintained a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
Novavax (NVAX)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Novavax today. The company’s shares closed last Tuesday at $7.44.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Novavax with a $10.67 average price target.
